{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:24:17Z","timestamp":1785795857277,"version":"3.56.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T00:00:00Z","timestamp":1439424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>High blood pressure (BP) levels expose patients treated with percutaneous coronary interventions (PCI) to very high risk of 10-year cardiovascular morbidity and mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To investigate the role of BP levels at the time of PCI on the risk of in-stent restenosis (ISR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We retrospectively included 796 patients previously treated with PCI, who underwent repeated angiography for recurrent angina or reversible myocardial ischemia. Patients were stratified into either case ( n = 354) and control ( n = 442) groups in the presence or absence of ISR (defined as in-stent diameter stenosis \u226550%). BP levels were measured at the time of first and second procedures. Normal BP levels were defined for &amp;lt;140\/90mm Hg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Patients with normal BP showed significantly higher ISR-free survival (Log-rank: 5.937; P = 0.015). Both systolic (HR (95% CI): 0.731 (0.590\u20130.906)) and systolic\/diastolic BP (HR (95% CI): 0.757 (0.611\u20130.939)) were significantly and independently associated with lower risk of ISR at Cox-regression analysis, adjusted for potential confounding factors, including stent type and concomitant medications. Patients with ISR showed lower rates of normal systolic\/diastolic BP values (166 (47%) vs. 254 (57%); P = 0.003) compared to controls. They also received higher stent number (1.40\u00b10.74 vs. 1.24\u00b10.51; P &amp;lt; 0.001) with higher stent length (24.3\u00b115.6 vs. 21.7\u00b113.9mm; P = 0.012), and lower rate of drug-eluting stents (DESs) (210 (48%) vs. 139 (40%); P = 0.025) compared to controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Normal BP at the time of PCI is associated with nearly 24% risk reduction of ISR as evaluated in a new angiography in patients with coronary artery disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpv131","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T23:59:50Z","timestamp":1439510390000},"page":"509-518","source":"Crossref","is-referenced-by-count":31,"title":["Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis"],"prefix":"10.1093","volume":"29","author":[{"given":"Giuliano","family":"Tocci","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza 1 , Sant\u2019Andrea Hospital, Rome , Italy ;"},{"name":"IRCCS Neuromed 2 , Pozzilli (IS) , Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[{"name":"Cardiovascular Center Aalst 3 , Aalst , Belgium ;"},{"name":"Department of Advanced Biomedical Sciences, Federico II University 4 , Naples , Italy ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Coluccia","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza 1 , Sant\u2019Andrea Hospital, Rome , Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Modestino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza 1 , Sant\u2019Andrea Hospital, Rome , Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beniamino","family":"Pagliaro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza 1 , Sant\u2019Andrea Hospital, Rome , Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Mastromarino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza 1 , Sant\u2019Andrea Hospital, Rome , Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giovannelli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza 1 , Sant\u2019Andrea Hospital, Rome , Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Berni","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza 1 , Sant\u2019Andrea Hospital, Rome , Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza 1 , Sant\u2019Andrea Hospital, Rome , Italy ;"},{"name":"IRCCS Neuromed 2 , Pozzilli (IS) , Italy ;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,13]]},"reference":[{"key":"2024012721425051600_CIT0001","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","article-title":"Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies","volume":"373","author":"Whitlock","year":"2009","journal-title":"Lancet"},{"key":"2024012721425051600_CIT0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archinte.1992.00400130082009","article-title":"Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group","volume":"152","author":"Neaton","year":"1992","journal-title":"Arch Intern Med"},{"key":"2024012721425051600_CIT0003","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"2024012721425051600_CIT0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-138-1-200301070-00006","article-title":"Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study","volume":"138","author":"Haider","year":"2003","journal-title":"Ann Intern Med"},{"key":"2024012721425051600_CIT0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"2024012721425051600_CIT0006","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"2024012721425051600_CIT0007","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"2024012721425051600_CIT0008","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"2024012721425051600_CIT0009","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/08037050903450468","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","volume":"18","author":"Mancia","year":"2009","journal-title":"Blood Press"},{"key":"2024012721425051600_CIT0010","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"2024012721425051600_CIT0011","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jash.2015.03.002","article-title":"Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension","volume":"9","author":"Rosendorff","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"2024012721425051600_CIT0012","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S","year":"2010","journal-title":"Eur Heart J"},{"key":"2024012721425051600_CIT0013","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet"},{"key":"2024012721425051600_CIT0014","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/heartjnl-2013-304933","article-title":"Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography","volume":"100","author":"Cassese","year":"2014","journal-title":"Heart"},{"key":"2024012721425051600_CIT0015","doi-asserted-by":"crossref","first-page":"24C","DOI":"10.1016\/0002-9149(91)90220-F","article-title":"Growth factors in pathogenesis of coronary arterial restenosis","volume":"68","author":"Cercek","year":"1991","journal-title":"Am J Cardiol"},{"key":"2024012721425051600_CIT0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00019501-200103000-00004","article-title":"Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty","volume":"12","author":"Tashiro","year":"2001","journal-title":"Coron Artery Dis"},{"key":"2024012721425051600_CIT0017","first-page":"S4","article-title":"Pathophysiology of coronary artery restenosis","volume":"3","author":"Schwartz","year":"2002","journal-title":"Rev Cardiovasc Med"},{"key":"2024012721425051600_CIT0018","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.addr.2006.01.015","article-title":"Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury","volume":"58","author":"Scott","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"2024012721425051600_CIT0019","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/17482940701263285","article-title":"Pathophysiology of coronary artery in-stent restenosis","volume":"9","author":"Kibos","year":"2007","journal-title":"Acute Card Care"},{"key":"2024012721425051600_CIT0020","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"2024012721425051600_CIT0021","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12588","article-title":"Admission blood pressure and 1-year mortality in acute myocardial infarction","author":"Roth","year":"2015","journal-title":"Int J Clin Pract"},{"key":"2024012721425051600_CIT0022","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection E, Treatment of High Blood Cholesterol in A","year":"2001","journal-title":"JAMA"},{"key":"2024012721425051600_CIT0023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00151642-200613040-00007","article-title":"Agabiti Rosei, President of the Italian Society of Hypertension","volume":"13","author":"Sesti","year":"2006","journal-title":"High Blood Pressure & Cardiovasc Prevent"},{"key":"2024012721425051600_CIT0024","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute\/American Heart Association Conference on Scientific Issues Related to Definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"2024012721425051600_CIT0025","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)","volume":"28","author":"Ryd\u00e9n","year":"2007","journal-title":"Eur Heart J"},{"key":"2024012721425051600_CIT0026","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"key":"2024012721425051600_CIT0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2261-10-35","article-title":"Prevalence of peripheral arterial disease in patients at non-high cardiovascular risk. Rationale and design of the PANDORA study","volume":"10","author":"Cimminiello","year":"2010","journal-title":"BMC Cardiovasc Disord"},{"key":"2024012721425051600_CIT0028","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"2024012721425051600_CIT0029","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"key":"2024012721425051600_CIT0030","first-page":"1462","article-title":"The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"28","author":"Mancia","year":"2007","journal-title":"Eur Heart J"},{"key":"2024012721425051600_CIT0031","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2024012721425051600_CIT0032","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"2024012721425051600_CIT0033","first-page":"393","article-title":"Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score","volume":"40","author":"Palmieri","year":"2004","journal-title":"Ann Ist Super Sanita"},{"key":"2024012721425051600_CIT0034","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/eurheartj\/ehq448","article-title":"Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score","volume":"32","author":"McGorrian","year":"2011","journal-title":"Eur Heart J"},{"key":"2024012721425051600_CIT0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/jhh.2013.3","article-title":"ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data","volume":"27","author":"Prieto-Merino","year":"2013","journal-title":"J Hum Hypertens"},{"key":"2024012721425051600_CIT0036","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2024012721425051600_CIT0037","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/HJH.0b013e32832d7370","article-title":"Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study","volume":"27","author":"Sleight","year":"2009","journal-title":"J Hypertens"},{"key":"2024012721425051600_CIT0038","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","article-title":"J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial","volume":"31","author":"Bangalore","year":"2010","journal-title":"Eur Heart J"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/4\/509\/2622369","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/4\/509\/2622369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T21:43:15Z","timestamp":1706391795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/4\/509\/2622369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,13]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,8,13]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpv131","relation":{},"ISSN":["1941-7225","0895-7061"],"issn-type":[{"value":"1941-7225","type":"electronic"},{"value":"0895-7061","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,4]]},"published":{"date-parts":[[2015,8,13]]}}}